A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus

References

• Adeshara KA, Diwan AG, Tupe RS. Diabetes and complications: cellular signaling pathways, current understanding and targeted therapies. Curr Drug Targets. 2016;17(11):1309–1328. doi:10.2174/138945011766615120912400726648059
   PubMed Web of Science ®Google Scholar
• Feudtner C. Diabetes: the sweet irony of modern technology. Bull World Health Organ. 2011;8(2):90–91. doi:10.2471/BLT.11.040211
   Web of Science ®Google Scholar
• Sarwar NGP, Seshasai SR, Gobin R, Kaptoge S, Di A. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging Risk Factors Collab. 2010;365:2215–2222.
   Google Scholar
• Sastre AA, Vernooij R, Harmand MG. Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6:CD003804.28617932
   PubMed Web of Science ®Google Scholar
• Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R D. 2015;15(3):227–232. doi:10.1007/s40268-015-0099-326254210
   PubMedGoogle Scholar
• Ena J, Gomez-Huelgas R, Sanchez-Fuentes D, et al. Management of patients with type 2 diabetes and multiple chronic conditions: a Delphi consensus of the Spanish Society of Internal Medicine. Eur J Intern Med. 2016;27:31–36. doi:10.1016/j.ejim.2015.10.01526586286
   PubMed Web of Science ®Google Scholar
• Jacobs E, Hoyer A, Brinks R, Icks A, Kuß O, Rathmann W. Healthcare costs of type 2 diabetes in Germany. Diabetic Med. 2017;34(6):855–861. doi:10.1111/dme.1333628199029
   PubMed Web of Science ®Google Scholar
• Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes – a global systematic review. PharmacoEconomics. 2015;33(8):811–831. doi:10.1007/s40273-015-0268-925787932
   PubMed Web of Science ®Google Scholar
• Wenjuan X, Liangxiao Z, Yuhong H, Qianxu Y, Hongbin X, Deqin Z. Discrimination of type 2 diabetes mellitus corresponding to different traditional Chinese medicine syndromes based on plasma fatty acid profiles and chemometric methods. J Ethnopharmacol. 2012;143(2):463–468. doi:10.1016/j.jep.2012.06.04522820238
   PubMed Web of Science ®Google Scholar
• Wang P, Sun H, Lv H, et al. Thyroxine and reserpine-induced changes in metabolic profiles of rat urine and the therapeutic effect of Liu Wei Di Huang Wan detected by UPLC-HDMS. J Pharm Biomed Anal. 2010;53(3):631–645. doi:10.1016/j.jpba.2010.04.03220605388
   PubMed Web of Science ®Google Scholar
• Dai B, Wu Q, Zeng C, et al. The effect of Liuwei Dihuang decoction on PI3K/Akt signaling pathway in liver of type 2 diabetes mellitus (T2DM) rats with insulin resistance. J Ethnopharmacol. 2016;192:382–389. doi:10.1016/j.jep.2016.07.02427401286
   PubMed Web of Science ®Google Scholar
• Tseng YT, Chang WH, Lin CC, Chang FR, Wu PC, Lo YC. Protective effects of Liuwei dihuang water extracts on diabetic muscle atrophy. Phytomedicine. 2019;53:96–106. doi:10.1016/j.phymed.2018.09.03230668418
   PubMed Web of Science ®Google Scholar
• Xu ZJ, Shu S, Li ZJ, Liu YM, Zhang RY, Zhang Y. Liuwei Dihuang pill treats diabetic nephropathy in rats by inhibiting of TGF-beta/SMADS, MAPK, and NF-kB and upregulating expression of cytoglobin in renal tissues. Medicine. 2017;96(3):e5879. doi:10.1097/MD.000000000000587928099346
   PubMed Web of Science ®Google Scholar
• Wang X, Sun H, Zhang A, Sun W, Wang P, Wang Z. Potential role of metabolomics approaches in the area of traditional Chinese medicine: as pillars of the bridge between Chinese and Western medicine. J Pharm Biomed Anal. 2011;55(5):859–868. doi:10.1016/j.jpba.2011.01.04221353755
   PubMed Web of Science ®Google Scholar
• Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110–120. doi:10.1016/S1875-5364(13)60037-023787177
   PubMed Web of Science ®Google Scholar
• Zhang G, Li Q, Chen Q. Network pharmacology: a new approach for Chinese Herbal Medicine Research. Evid Based Complement Alternat Med. 2013;2013(8):621423.23762149
   PubMedGoogle Scholar
• Mao Y, Hao J, Jin ZQ, et al. Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients. Oncotarget. 2017;8(16):27007–27021. doi:10.18632/oncotarget.1535128212580
   PubMedGoogle Scholar
• Zeng L, Yang K. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach. J Ethnopharmacol. 2017;199:68–85. doi:10.1016/j.jep.2017.01.04528130113
   PubMed Web of Science ®Google Scholar
• Zuo H, Zhang Q, Su S, Chen Q, Yang F, Hu Y. A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: an example of Yu Ping Feng decoction. Sci Rep. 2018;8:1. doi:10.1038/s41598-018-29764-129311619
   PubMed Web of Science ®Google Scholar
• Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S, Aittokallio T. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015;32(8):1249–1266. doi:10.1039/c5np00005j26030402
   PubMed Web of Science ®Google Scholar
• Lee AY, Park W, Kang TW, Cha MH, Chun JM. Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis. J Ethnopharmacol. 2018;221:151–159. doi:10.1016/j.jep.2018.04.02729698773
   PubMed Web of Science ®Google Scholar
• Kang D, Pang XC, Ying Z, et al. Network pharmacology-based analysis of Chinese herbal NaoDeSheng formula for application to Alzheimer disease. Chin J Nat Med. 2018;16(1):53–62. doi:10.1016/S1875-5364(18)30029-329425590
   PubMed Web of Science ®Google Scholar
• Jinlong R, Peng L, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;16(1):13.
   Google Scholar
• Huang J, Cheung F, Tan HY, et al. Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology. Mol Med Rep. 2017;16(4):4583–4592. doi:10.3892/mmr.2017.714928791364
   PubMed Web of Science ®Google Scholar
• Liu Z, Guo F, Wang Y, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine. Sci Rep. 2016;6:21146. doi:10.1038/srep2114626879404
   PubMed Web of Science ®Google Scholar
• Li B, Rui J, Ding X, Yang X. Exploring the multicomponent synergy mechanism of Banxia Xiexin Decoction on irritable bowel syndrome by a systems pharmacology strategy. J Ethnopharmacol. 2019;233:158–168. doi:10.1016/j.jep.2018.12.03330590198
   PubMed Web of Science ®Google Scholar
• Breuza L, Poux S, Estreicher A, et al. The UniProtKB guide to the human proteome. Database (Oxford). 2016;2016:bav120.26896845
   PubMed Web of Science ®Google Scholar
• Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses: the GeneCards suite. Cur Protoc Bioinf. 54(1), 1–302016.
   PubMedGoogle Scholar
• Amberger JS, Hamosh A. Searching Online Mendelian Inheritance in Man (OMIM): a knowledgebase of human genes and genetic phenotypes. Cur Protoc Bioinf. 2017;58(1):1–2.
   Google Scholar
• Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for metastatic breast cancer – an anachronism in the era of personalised and targeted oncological therapy? Geburtshilfe Frauenheilkd. 2015;75(6):574–583. doi:10.1055/s-0035-154615026166838
   PubMed Web of Science ®Google Scholar
• Minoru K. A database for post-genome analysis. Trends Genet. 1997;13 375–376.9287494
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–D361. doi:10.1093/nar/gkw109227899662
   PubMed Web of Science ®Google Scholar
• Xu WM, Yang K, Jiang LJ, Hu JQ, Zhou XZ. Integrated modules analysis to explore the molecular mechanisms of phlegm-stasis cementation syndrome with ischemic heart disease. Front Physiol. 2018;9:7. doi:10.3389/fphys.2018.0000729403392
   PubMed Web of Science ®Google Scholar
• Qian B, Junyang L, Chao H, et al. Topological, functional, and dynamic properties of the protein interaction networks rewired by benzo(a)pyrene. Toxicol Appl Pharmacol. 2015;283(2):83–91. doi:10.1016/j.taap.2015.01.00625596431
   PubMed Web of Science ®Google Scholar
• Guo R, Zhang X, Su J, et al. Identifying potential quality markers of Xin-Su-Ning capsules acting on arrhythmia by integrating UHPLC-LTQ-Orbitrap, ADME prediction and network target analysis. Phytomedicine. 2018;44:117–128. doi:10.1016/j.phymed.2018.01.01929526583
   PubMed Web of Science ®Google Scholar
• Gary D, Bader CWH. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4(2):1–27.12513700
   PubMed Web of Science ®Google Scholar
• Ni M, Liu X, Wu J, et al. Identification of candidate biomarkers correlated with the pathogenesis and prognosis of non-small cell lung cancer via integrated bioinformatics analysis. Front Genet. 2018;9:469. doi:10.3389/fgene.2018.0017330369945
   PubMed Web of Science ®Google Scholar
• Fang E, Zhang X. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis. Cancer Biomark. 2017;21(1):373–381. doi:10.3233/CBM-17055029081411
   PubMed Web of Science ®Google Scholar
• Vilar S, Cozza G, Moro S. Medicinal chemistry and the Molecular Operating Environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem. 2008;8(18):1555–1572. doi:10.2174/15680260878678662419075767
   PubMed Web of Science ®Google Scholar
• Maier JK, Labute P. Assessment of fully automated antibody homology modeling protocols in molecular operating environment. Proteins. 2014;82(8):1599–1610. doi:10.1002/prot.2457624715627
   PubMed Web of Science ®Google Scholar
• Andrews M, Leiva E, Arredondo-Olguín M. Short repeats in the heme oxygenase 1 gene promoter is associated with increased levels of inflammation, ferritin and higher risk of type-2 diabetes mellitus. J Trace Elem Med Biol. 2016;37:25–30. doi:10.1016/j.jtemb.2016.06.00127473828
   PubMed Web of Science ®Google Scholar
• Lee EY, Lee YH, Kim SH, et al. Association between heme oxygenase-1 promoter polymorphisms and the development of albuminuria in type 2 diabetes: a case-control study. Medicine. 2015;94(43):e1825. doi:10.1097/MD.000000000000087426512585
   PubMed Web of Science ®Google Scholar
• Lee SE, Lee YB, Jun JE, et al. Increment of serum bilirubin as an independent marker predicting new-onset type 2 diabetes mellitus in a Korean population. Nutr Metab Cardiovasc Dis. 2017;27(3):234–240. doi:10.1016/j.numecd.2016.10.00327989511
   PubMed Web of Science ®Google Scholar
• George S. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304(5675):1325–1328. doi:10.1126/science.109670615166380
   PubMed Web of Science ®Google Scholar
• Chen WS, Peng X-D, Wang Y, et al. Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. Mol Cell Biol. 2009;29(11):3151. doi:10.1128/MCB.01792-0819289493
   PubMed Web of Science ®Google Scholar
• Yin X, Xu Z, Zhang Z, et al. Association of PI3K/AKT/mTOR pathway genetic variants with type 2 diabetes mellitus in Chinese. Diabetes Res Clin Pract. 2017;128:127–135. doi:10.1016/j.diabres.2017.04.00228477532
   PubMed Web of Science ®Google Scholar
• Fathy SA, Mohamed MR, Ali MAM, El-Helaly AE, Alattar AT. Influence of IL-6, IL-10, IFN-gamma and TNF-alpha genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers. 2018;24:1–13.30126309
   PubMed Web of Science ®Google Scholar
• Senthilkumar GP, Anithalekshmi MS, Yasir M, Parameswaran S, Packirisamy RM, Bobby Z. Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy. Diabetes Metab Syndr. 2018;12(1):23–26. doi:10.1016/j.dsx.2017.08.00528864059
   PubMed Web of Science ®Google Scholar
• Kologrivova IV, Suslova TE, Koshel’Skaya OA, Vinnitskaya IV, Trubacheva OA. System of matrix metalloproteinases and cytokine secretion in type 2 diabetes mellitus and impaired carbohydrate tolerance associated with arterial hypertension. Bull Exp Biol Med. 2014;156(5):635–638. doi:10.1007/s10517-014-2413-424770746
   PubMed Web of Science ®Google Scholar
• EH CN K, Saha PK, Xiao L, et al. miR-30a remodels subcutaneous adipose tissue inflammation to improve insulin sensitivity in obesity. Diabetes. 2018;67(12):2541–2553. doi:10.2337/db17-137830002134
   PubMed Web of Science ®Google Scholar
• M WN C, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;2:S97–107.
   Google Scholar
• Yamada YMH, Watanabe S, Kato K, et al. Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Int J Mol Med. 2007;20(5):703–707.17912464
   PubMed Web of Science ®Google Scholar
• Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? J Cell Biochem. 2017;118(11):3577–3585. doi:10.1002/jcb.2609728460155
   PubMed Web of Science ®Google Scholar
• Liu C, Wan X, Ye T, et al. Matrix metalloproteinase 2 contributes to pancreatic beta cell injury induced by oxidative stress. PLoS One. 2014;9(10):e110227. doi:10.1371/journal.pone.011022725333278
   PubMed Web of Science ®Google Scholar
• Kostov K, Blazhev A, Atanasova M, Dimitrova A. Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in pre-hypertensive and hypertensive patients with type 2 diabetes. Int J Mol Sci. 2016;17(8). doi:10.3390/ijms17081182
   PubMed Web of Science ®Google Scholar
• Ma YZ, Jiang QY, Kong DQ. Association between matrix metallopeptidase 1 and type 2 diabetes mellitus coexisting with coronary heart disease in a Han Chinese population. Genet Mol Res. 2016;15(2). doi:10.4238/gmr.15027938
   Web of Science ®Google Scholar
• Chasseaud LF. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv Cancer Res. 1979;29(29):175–274.474272
   PubMedGoogle Scholar
• Antas P, Carneiro M, Reis B, et al. GST transcriptional changes induced by a toxic Microcystis aeruginosa strain in two bivalve species during exposure and recovery phases. Ecotoxicology. 2018;27(9):1272–1280. doi:10.1007/s10646-018-1980-y30242593
   PubMed Web of Science ®Google Scholar
• Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of glutathione transferases implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J. 2001;360(1):1–16. doi:10.1042/0264-6021:360000111695986
   PubMed Web of Science ®Google Scholar
• Tang ST, Wang CJ, Tang HQ, Zhang Q, Wang Y. Evaluation of glutathione S-transferase genetic variants affecting type 2 diabetes susceptibility: a meta-analysis. Gene. 2013;530(2):301–308. doi:10.1016/j.gene.2013.08.04324008019
   PubMed Web of Science ®Google Scholar
• Babelova A, Burckhardt BC, Salinas-Riester G, Pommerenke C, Burckhardt G, Henjakovic M. Next generation sequencing of sex-specific genes in the livers of obese ZSF1 rats. Genomics. 2015;106(4):204–213. doi:10.1016/j.ygeno.2015.07.00626200819
   PubMed Web of Science ®Google Scholar
• Stoian A, Banescu C, Balasa RI, et al. Influence of GSTM1, GSTT1, and GSTP1 polymorphisms on type 2 diabetes mellitus and diabetic sensorimotor peripheral neuropathy risk. Dis Markers. 2015;2015:638693. doi:10.1155/2015/10535826435566
   PubMed Web of Science ®Google Scholar
• Takako Yokozawa, Kim HY, Yamabe N. Amelioration of diabetic nephropathy by dried Rehmanniae Radix (Di Huang) extract. Am J Chin Med (Gard City N Y). 2004;32(6):829–839. doi:10.1142/S0192415X04002442
   Web of Science ®Google Scholar
• Xing L, Dai G, Gaohong L, et al. Synergistic interaction of effective parts in Rehmanniae Radix and Cornus officinalis ameliorates renal injury in C57BL/KsJ-db/db diabetic mice: involvement of suppression of AGEs/RAGE/SphK1 signaling pathway. J Ethnopharmacol. 2016;185:110–119. doi:10.1016/j.jep.2016.03.01726972502
   PubMed Web of Science ®Google Scholar
• Qian DS, Zhu YF, Zhu Q. Effect of alcohol extract of cornus officinalis Sieb. et Zucc on GLUT4 expression in skeletal muscle in type 2 (non-insulin-dependent) diabetic mellitus rats. Zhongguo Zhong Yao Za Zhi. 2001;26(12):859–862.12776340
   PubMedGoogle Scholar
• Zhang M-H, Feng L, Zhu M-M, et al. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and high-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol. 2014;151(1):591–600. doi:10.1016/j.jep.2013.11.01524269777
   PubMed Web of Science ®Google Scholar
• Li Q, Li W, Gao Q, Zou Y. Hypoglycemic effect of Chinese Yam (Dioscorea opposita rhizoma) polysaccharide in different structure and molecular weight. J Food Sci. 2017;82(10):2487–2494. doi:10.1111/1750-3841.1391928906544
   PubMed Web of Science ®Google Scholar
• Hsu PC, Tsai YT, Lai JN, Wu CT, Lin SK, Huang CY. Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol. 2014;156:358–364. doi:10.1016/j.jep.2014.08.02925178949
   PubMed Web of Science ®Google Scholar
• Akash MSH, Kanwal R, Shuqing C. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2013;114(3):525–531. doi:10.1002/jcb.2440222991242
   PubMed Web of Science ®Google Scholar
• Akash MS, Rehman K, Liaqat A. Liaqat A tumor necrosis factor-alpha role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–110. doi:10.1002/jcb.2617428569437
   PubMed Web of Science ®Google Scholar
• Chawla D, Bansal S, Banerjee BD, Madhu SV, Kalra OP, Tripathi AK. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications. Microvasc Res. 2014;95:1–6. doi:10.1016/j.mvr.2014.06.01024984291
   PubMed Web of Science ®Google Scholar
• Koulis C, Watson AM, Gray SP, Jandeleit-Dahm KA. Linking RAGE and Nox in diabetic micro- and macrovascular complications. Diabetes Metab. 2015;41(4):272–281. doi:10.1016/j.diabet.2015.01.00626323666
   PubMed Web of Science ®Google Scholar
• Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2008;295(2):H491. doi:10.1152/ajpheart.00464.200818539754
   PubMed Web of Science ®Google Scholar
• Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res. 2016;2016:6809703. doi:10.1155/2016/680970327547766
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T, Nakamura K. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes. Med Hypotheses. 2008;71(5):749–751. doi:10.1016/j.mehy.2008.05.03918710793
   PubMed Web of Science ®Google Scholar
• Tan KCB, Chow WS, Ai VHG, Metz C, Bucala R, Lam KSL. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002;25(6):1055. doi:10.2337/diacare.25.6.105512032114
   PubMed Web of Science ®Google Scholar
• Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280(5):E685–E694. doi:10.1152/ajpendo.2001.280.5.E68511287350
   PubMed Web of Science ®Google Scholar
• Csiszar AUZ. Endothelial dysfunction and vascular inflammation in type 2 diabetes interaction of AGE-RAGE and TNF-α signaling. Am J Physiol Heart Circ Physiol. 2008;295(2):H475. doi:10.1152/ajpheart.00644.200818599592
   PubMed Web of Science ®Google Scholar
• Xue G, Souad B, Andrea P, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation. 2007;115(2):245–254. doi:10.1161/CIRCULATIONAHA.106.65067117200442
   PubMed Web of Science ®Google Scholar
• Andrea P, Xue G, Souad B, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99(1):69–77. doi:10.1161/01.RES.0000229685.37402.8016741160
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhu S, Chang S, et al. Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: role of NF-kappa B signaling. Eur J Pharmacol. 2013;720(1–3):147–157.24436987
   PubMed Web of Science ®Google Scholar
• Kim HS, Han MS, Chung KW, et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity. 2007;27(2):321–333. doi:10.1016/j.immuni.2007.06.01017707128
   PubMed Web of Science ®Google Scholar
• Dasu MR, Martin SJ. Toll-like receptor expression and signaling in human diabetic wounds. World J Diabetes. 2014;5(2):219–223. doi:10.4239/wjd.v5.i2.21924748934
   PubMedGoogle Scholar
• Mali V, Haddox S, Hornersmith C, Matrougui K, Belmadani S. Essential role for EGFR tyrosine kinase and ER stress in myocardial infarction in type 2 diabetes. Pflugers Arch. 2018;470(3):471–480. doi:10.1007/s00424-017-2097-529288332
   PubMed Web of Science ®Google Scholar
• Souad B, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Khalid M. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes. 2008;57(6):1629–1637. doi:10.2337/db07-073918319304
   PubMed Web of Science ®Google Scholar
• Prada PO, Ropelle ER, Mourão RH, et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes. 2009;58(12):2910. doi:10.2337/db08-050619696185
   PubMed Web of Science ®Google Scholar
• Z LY L, Overstreet JM, Chung S, et al. Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes. Diabetes. 2018;67(9):1847–1857. doi:10.2337/db17-151329959129
   PubMed Web of Science ®Google Scholar
• Chen S, Jiang H, Wu X, Fang J. Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. Mediators Inflamm. 2016;2016:9340637. doi:10.1155/2016/934063728003714
   PubMed Web of Science ®Google Scholar
• Zheng J, Wu J, Chen J, et al. Therapeutic effects of quercetin on early inflammation in hypertriglyceridemia-related acute pancreatitis and its mechanism. Pancreatology. 2016;16(2):200–210. doi:10.1016/j.pan.2016.01.00526873426
   PubMed Web of Science ®Google Scholar
• Xu XH, Zhao C, Peng Q, Xie P, Liu QH. Kaempferol inhibited VEGF and PGF expression and in vitro angiogenesis of HRECs under diabetic-like environment. Braz J Med Biol Res. 2017;50(3):e5396. doi:10.1590/1414-431X2017607128273207
   PubMed Web of Science ®Google Scholar
• MB G, Rathmann W, Charbonnel B, et al. Treatment of type 2 diabetes mellitus worldwide: baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract. 2019;151:20–32. doi:10.1016/j.diabres.2019.03.02430904743
   PubMed Web of Science ®Google Scholar
• Health AGDo, Ageing. What is diabetes? Australian Government Department of Health & Ageing. 2006;1:1-2. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pq.
   Google Scholar